Why Mustang Bio's Stock Is Trading Higher Today

Mustang Bio Inc MBIO announced that final data from the follicular lymphoma cohort of the single-institution Phase 1/2 clinical trial of MB-106 demonstrate treatment with the CD20-targeted, autologous CAR T-cell therapy resulted in high overall response (ORR) and complete response (CR) rates and CAR T persistence

MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center to treat patients with relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia.

20 patients with relapsed FL with confirmed CD20 expression participated in the study. ORR was 95% (19/20), and the CR rate was 80% (16/20). 

Patients who received higher dose levels had an ORR of 100% and a CR rate of 91%. Ten patients are in remission over one year, seven of whom are over two years. 

One patient, previously treated with a CD19-targeted CAR T-cell therapy, achieved a CR and remains in remission after 18 months. 

From a safety profile perspective, all cytokine release syndrome events were grade 1 or grade 2, with no grade ≥ 3 CRS events. There was no occurrence of immune effector cell-associated neurotoxicity syndrome of any grade.

Price Action: MBIO shares are up 9.44% at $8.00 on the last check Friday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!